Epidemology of Acute Kidney Injury in Diabetic Patients Infected With covid_19 In Assiut University Hospital

The novel coronavirus SARS-CoV-2 was identified as the causative agent for a series of atypical respiratory diseases in Wuhan, China in December of 2019(.1) The disease termed COVID-19, was officially declared a pandemic by the World Health Organization on March 11, 2020. SARS-CoV-2 contains a single-stranded, positive-sense RNA genome surrounded by an extracellular membrane containing a series of spike glycoproteins resembling a crown.COVID-19 infection results in diverse symptoms and morbidity depending on individual genetics, ethnicity, age, and geographic location. In severe cases, COVID-19 pathophysiology includes destruction of lung epithelial cells, thrombosis, hypercoagulation, and vascular leak leading to sepsis.(2) COVID-19 risk factors include cardiovascular disease, hypertension, and diabetes.(2)

Study Overview

• Status: Not yet recruiting
• Conditions: Acute Kidney Injury Due to covid_19
• Intervention / Treatment: Diagnostic test: laboratory

Detailed Description

Notably, in several studies, diabetes is one of the most reported comorbidities with poor prognosis in patients with severe COVID-19 due to Compromised innate immunity, pro-inflammatory cytokine reduced expression of ACE2 and use of renin-angiotensin-aldosterone system antagonists. (3) On the other hand, COVID-19 contributes to worsening of dysglycemia in people with diabetes mellitus by direct β-cell damage, cytokine-induced insulin resistance, hypokalemia and drugs used in the treatment of COVID-19 (like corticosteroids, lopinavir/ritonavir).(4) Nearly half of critically ill patients would develop AKI at some point during their ICU admission.(5) Acute kidney injury (AKI) has been reported to be the second observed complication in deceased patients after ARDS.it is reported that patients who died with covid19 had different degrees of AKI .The pathogenesis of kidney injury in patients infected with covid19 is multifactorial: (1) prerenal azotemia, ATN can occur owing to many contributing factors including volume depletion, cytokine storm, hypoxia, shock, or rhabdomyolysis (2) proximal tubular injury, (3) glomerulopathy, (4) thrombotic microangiopathy, and (5)complications from the treatment of COVID_19. (6)

• Study Type: Observational
• Enrollment (Anticipated): 100

Contacts and Locations

• Study Contact: Name: doaa DR rezk, master; Phone Number: +20 01007749061; Email: doaa011180@med.aun.edu.eg

Study Locations

• Egypt
  • Assiut, Egypt
    • Doaa Ramadan Rezk
    • Contact: Doaa DR Ramadan, master; Phone Number: +20 01007749061; Email: doaa011180@med.aun.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: ADULT; OLDER_ADULT; CHILD
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

The Data will be collected by a questionnaire includes the followings:

• Socio demographic data (name, age, sex, Body weight and height, job, marital status, number of children, educational level and residence etc).
• Main presenting symptoms
• History of hypertension, chronic kidney disease, ect.

Description

Inclusion Criteria:

• patients admitted because of COVID-19 infetion.

Exclusion Criteria:

• Patients with ESRD on regular dialysis ,Patients with stage 4 or 5 non-dialysis if the condition proven to be progression of the already known diagnosis.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
covid not diabetic with AKI; AKI in pt with covid_19 not diabetic	Diagnostic test: laboratory; laboratory data
AKI in covid_19 in diabetic; AKI in covid_19 in diabetic pt	Diagnostic test: laboratory; laboratory data
covid_19 in diabetic; covid_19 in diabetic without AKI	Diagnostic test: laboratory; laboratory data

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
percentage of AKI in covid_19 in diabetic pt	diabetic pt with AKI due to infection with covid _19	6 months

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Principal Investigator: doaa DR rezk, master, University Hospital

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): October 1, 2021
• Primary Completion (ANTICIPATED): February 20, 2022
• Study Completion (ANTICIPATED): March 20, 2022

Study Registration Dates

• First Submitted: October 1, 2021
• First Submitted That Met QC Criteria: October 9, 2021
• First Posted (ACTUAL): October 12, 2021

Study Record Updates

• Last Update Posted (ACTUAL): October 12, 2021
• Last Update Submitted That Met QC Criteria: October 9, 2021
• Last Verified: October 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Renal Insufficiency; Wounds and Injuries; Acute Kidney Injury
• Other Study ID Numbers: Acute kidney in covid_19

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated device product: No